2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-121161
    (Rac)-Brassinazole 224047-41-0 98%
    (Rac)-Brassinazole, triazole-type compound, is a brassinosteroid (BR) biosynthesis inhibitor. (Rac)-Brassinazole increases inhibition of CYP90B in BR biosynthesis
    (Rac)-Brassinazole
  • HY-121307
    Gliamilide 51876-98-3 98%
    Gliamilide is an active and well tolerated sulfamylurea derivative and displays a very short plasma half-life. Gliamilide is promising for research of maturity-onset diabetic deseases.
    Gliamilide
  • HY-121424
    Glutamylputrescine 58316-51-1 98%
    Glutamylputrescine is a nucleoside metabolite.
    Glutamylputrescine
  • HY-121455
    Lamtidine 73278-54-3 98%
    Lamtidine is a histamine H2 receptor antagonist. Lamtidine has analogues and derivatives that exhibit stronger activity.
    Lamtidine
  • HY-121500
    R-116010 355860-40-1 98%
    R-116010 is a potent and selective retinoic acid (RA) metabolism inhibitor and can inhibit hydroxylase CYP26. R-116010 can enhance the anti-tumor effect of retinoic acid drugs. R-116010 can be used for the research of cancer, metabolic and neurological disease, such as neuroblastoma.
    R-116010
  • HY-121542
    PPARδ agonist 10 685139-10-0 98%
    PPARδ agonist 10 (compound 7) is an orally active, selective, and partial agonist of PPARδ, with EC50 values of 0.053 μM and 0.30 µM for hPPARδ(LBD)-GAL4 and mPPARδ, respectively. PPARδ agonist 10 is a partial PPARδ agonist in transactivation assay but a full agonist on free fatty acids (FFA) oxidation in muscle cells both in vitro and in vivo. PPARδ agonist 10 can be used for dyslipidemia research.
    PPARδ agonist 10
  • HY-121565
    SaRI 59-801 80565-58-8 98%
    SaRI 59-801 is an orally effective hypoglycemic compound with stimulation activity of insulin secretion. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice.
    SaRI 59-801
  • HY-121583
    Gemcadiol 35449-36-6 98%
    Gemcadiol is a potent antilipemic agent. Gemcadiol has the potential for the research of hyperlipoproteinemia.
    Gemcadiol
  • HY-121746
    GW7845 196809-22-0 98%
    GW7845 is an orally active non-thiazolidinedione, tyrosine-derived PPARγ agonist. GW7845 is effective at inhibiting voltage-dependent calcium channels (VDCC) and relaxing pressurized arteries with IC50 of 3 μM by using Ba2+ as the charge carrier through VDCC. GW7845-induced apoptosis is mitochondria- and apoptosome-dependent. GW7845 induces rapid mitochondrial membrane depolarization and release of cytochrome c in primary pro-B cells and BU-11 cells.
    GW7845
  • HY-121859
    RU28362 74915-64-3 98%
    RU28362 is a potent and selective glucocorticoid agonist. RU28362 increases the Bnip3 mRNA levels in neurons. RU28362 inhibits adrenocorticotrophic hormone (ACTH) and corticosterone secretion. RU28362 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    RU28362
  • HY-121888
    20-HEPE 116477-57-7 98%
    20-HEPE is a metabolite of eicosapentaenoic acid formed by ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. At 10 μM, it activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter gene. 20-HEPE also activates mouse transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks analgesic activity in rats.
    20-HEPE
  • HY-121933
    IDD388 314297-26-2 99.40%
    IDD388 is a selective aldose reductase (ALR2) inhibitor with an IC50 of 30 nM. IDD388 displays selectivity for ALR2 over ALR1 (IC50 of 14 μM).
    IDD388
  • HY-121968
    (Z)-α-Methylcinnamaldehyde 66051-14-7 98%
    (Z)-α-Methylcinnamaldehyde is an organic compound that is characterized by its distinct aldehyde and aromatic ring structures. (Z)-α-Methylcinnamaldehyde is an impurity that can be found in a pharmaceutical drug used for diabetic neuropathy–Epalrestat.
    (Z)-α-Methylcinnamaldehyde
  • HY-122078
    FR-190809 215589-63-2 98%
    FR-190809 is a potent, nonadrenotoxic, orally efficacious acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor, with an IC50 of 45 nM.
    FR-190809
  • HY-122133
    CI 750 47739-68-4 98%
    CI 750 is an orally active antidiarrheal agent. CI 750 exhibits antidiarrheal activity in monkeys and rats. CI 750 can be used for the research of diarrhea.
    CI 750
  • HY-122147
    L-644698 72313-41-8 98%
    L-644698 is a potent and selective human recombinant prostaglandin D2 (PGD2) receptor (hDP) agonist with Ki values of 0.9, 267, 3730, 9280 nM for hDP, hEP2, hEP3, hEP4, respectively. L-644698 induces cyclic AMP production with an EC50 value of 0.5 nM.
    L-644698
  • HY-122148
    DA 4626 83184-14-9 98%
    DA 4626 is a competitive H2-histamine receptor antagonist. DA 4626 inhibits adenylate cyclase activity with a KB value of 40 nM.
    DA 4626
  • HY-122159
    MDPD 693265-89-3 98%
    MDPD is an Arabidopsis FAAH (AtFAAH) activator that can enhance the enzymatic activity of AtFAAH.
    MDPD
  • HY-12216S
    Resmetirom-13C3,15N
    Resmetirom-13C3,15N (MGL-3196-13C3,15N) is the 13C- and 15N-labeled Resmetirom (HY-12216). Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis.
    Resmetirom-13C3,15N
  • HY-122188
    TAK-100 907609-33-0 98%
    TAK-100 is a selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor with an IC50 of 5.3 nM. TAK-100 hass little or no inhibitory effects on other dipeptidyl peptidase members. TAK-100 can be used for the study of diabetes.
    TAK-100
Cat. No. Product Name / Synonyms Application Reactivity